Lingohr Asset Management GmbH Makes New $354,000 Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Lingohr Asset Management GmbH bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,878 shares of the specialty pharmaceutical company’s stock, valued at approximately $354,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth $9,335,000. Moloney Securities Asset Management LLC acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth $464,000. Pacer Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on JAZZ shares. Piper Sandler reissued an “overweight” rating and set a $176.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $140.00 to $150.00 in a research report on Wednesday, February 26th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Barclays reissued an “overweight” rating and set a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, Morgan Stanley reissued an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $187.71.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 2,403 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $138.41, for a total transaction of $332,599.23. Following the sale, the chief marketing officer now directly owns 79,621 shares in the company, valued at $11,020,342.61. This represents a 2.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,022,825 over the last three months. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ:JAZZ opened at $142.07 on Thursday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market capitalization of $8.63 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The firm’s 50-day moving average is $130.66 and its two-hundred day moving average is $121.32. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.